Referencia número: HY-19832

SC66

5 Cited Publications

Revisión del cliente

Based on 5 publication(s) in Google Scholar

SC66 is an Akt inhibitor, reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.65%
No. CAS: 871361-88-5
Fòrmula: C₁₈H₁₆N₂O
Peso molecular:276.33

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

SC66 Chemical Structure

No. CAS: 871361-88-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

SC66 is an Akt inhibitor, reduces cell viability in a dose- and time-dependent manner, inhibits colony formation and induces apoptosis in hepatocellular carcinoma (HCC) cells.

IC₅₀ & Target

Akt^[1]

Ver todos los productos específicos de isoformas Akt :

Cellular Effect

Cell Line	Type	Value	Description	References
HT-29	IC₅₀	2.35 μM Compound: AN3	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22551677]
K562	IC₅₀	2.5 μM Compound: A1	Inhibition of NF-kappaB activation in human K562 cells Inhibition of NF-kappaB activation in human K562 cells	[PMID: 20728364]
L929	IC₅₀	>250 μM Compound: 10	Trypanocidal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells assessed as parasite growth inhibition after 7 days by beta-galactosidase assay Trypanocidal activity against Trypanosoma cruzi Tulahuen amastigotes infected in mouse L929 cells assessed as parasite growth inhibition after 7 days by beta-galactosidase assay	[PMID: 24321832]
MDA-MB-231	EC₅₀	1.1 μM Compound: A1	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 20728364]
MDA-MB-468	EC₅₀	1.9 μM Compound: A1	Cytotoxicity against human MDA-MB-468 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells after 72 hrs by SRB assay	[PMID: 20728364]
NB-4	IC₅₀	0.27 μM Compound: 26	Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human NB4 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24960549]
PANC-1	IC₅₀	2.18 μM Compound: AN3	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 22551677]
PC-3	IC₅₀	2.12 μM Compound: AN3	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22551677]
Peritoneal macrophage cell	CC₅₀	23.9 μM Compound: 10	Cytotoxicity against mouse peritoneal macrophages after 24 hrs by MTT assay Cytotoxicity against mouse peritoneal macrophages after 24 hrs by MTT assay	[PMID: 24321832]
SK-BR-3	IC₅₀	0.2 μM Compound: A1	Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay	[PMID: 20728364]
SUP-T1	CC₅₀	0.82 μM Compound: UHLMT-70	Cytotoxicity against human SUP-T1 cells assessed as reduction in cell viability incubated for 16 hrs by MTT assay Cytotoxicity against human SUP-T1 cells assessed as reduction in cell viability incubated for 16 hrs by MTT assay	[PMID: 37473689]

In Vitro

SC66 inhibits cell viability and colony forming capacity of HCC cells with IC₅₀s of 0.77，0.47，0.92，0.75 and 2.85 μg/mL at 72 hours for HepG2, Hep3B, PLC/PRF/5，HA22T/VGH and Huh7 cells. HepG2, HA22T/VGH and PLC/PRF/5 cells have similar IC₅₀s of approximately 0.85 and 0.75 μg/mL at 48 and 72 hours, respectively. To determine whether the decrease in cell viability is related to apoptosis induction, TUNEL assays are performed in Hep3B and Huh7 cells treated with 1, 2 and 4 μg/mL of SC66 for 24 hours. In Hep3B cells the number of TUNEL-positive cells increased with increasing concentrations of SC66, whereas in Huh7 cells very few light brown-colored cells are observed only after treatment with 4 μg/mL SC66^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To demonstrate the effectiveness in vivo of SC66 on HCC, a mouse xenograft tumor model of Hep3B cells is used. When tumors became palpable, at a size of about 150 mm³, mice are randomized into three groups of 6 animals each. The treated group receive SC66 at 15 and 25 mg/kg twice a week via i.p. injection, while the untreated group receive the vehicle alone. Treatment with 25 mg/Kg SC66 significantly reduces tumor volume to 37% on day 17 when compared with tumors of the untreated group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 871361-88-5
Appearance Solid
Peso molecular 276.33
Fòrmula C₁₈H₁₆N₂O
Color Light yellow to yellow
SMILES

O=C1/C(CCC/C1=C\C2=CC=NC=C2)=C/C3=CC=NC=C3
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All WB

Sort by:

Journal Impact Factor

Cell Death Dis

The therapeutic value of SC66 in human renal cell carcinoma cells. [Abstract]

2020 May 11;11(5):353. PMID: 32393791

SC66 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 11;11(5):353. [Abstract]

786-O RCC cellsare treated with indicated concentration of SC66, cells are further cultured for applied time periods expression of apoptosis-associated proteins.
Cancer Biol Ther

RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-β pathway. [Abstract]

2024 Dec 31;25(1):2321770. PMID: 38444223
Front Pharmacol

AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway. [Abstract]

2020 Jul 31;11:1102. PMID: 32848734
Toxicology

SIRT4 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the AKT/mTOR/Autophagy Pathway. [Abstract]

2022 Feb 5;469:153119. PMID: 35134463
Molecules

Geniposidic Acid from Eucommia ulmoides Oliver Staminate Flower Tea Mitigates Cellular Oxidative Stress via Activating AKT/NRF2 Signaling. [Abstract]

2022 Dec 5;27(23):8568. PMID: 36500666

Solvente y solubilidad

In Vitro:

DMSO : 25 mg/mL (90.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6189 mL

18.0943 mL

36.1886 mL

5 mM

0.7238 mL

3.6189 mL

7.2377 mL

10 mM

0.3619 mL

1.8094 mL

3.6189 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[1]

Cells (5 ×10³/well) are distributed into each well of 96-well microtiter plates and then incubated overnight. At time 0, the medium is replaced with fresh complete medium and different doses of SC66 are added. Cells are cultured for 24, 48 and 72 hours. At the end of treatment, MTS assays are performed using the CellTiter Aqueous OneSolution kit. Cell viability is expressed as a percentage of the absorbance measured in the control cells. Values are expressed as means±SD of three separate experiments, each performed in triplicate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Male nude athymic mice (Fox1 nu/nu) aged 4 weeks are used. Suspensions of 1×10⁷ Hep3B cells in 0.2 mL of PBS are inoculated into the right flank of the animal. When tumors became palpable (around 150 mm³), the mice are randomly divided into three groups of 6 animals each, with the various tumor volumes equally distributed among the three groups. Two groups of mice are treated twice a week with 15 and 25 mg/kg SC66 suspended in DMSO, further diluted in a solution of 25% ethanol and administered via i.p. injection. The control group receive the vehicle alone. Tumor volumes are determined twice a week using calipers. Primary tumor volumes are calculated.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Cusimano A, et al. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015 Jan 30;6(3):1707-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6189 mL	18.0943 mL	36.1886 mL	90.4715 mL
	5 mM	0.7238 mL	3.6189 mL	7.2377 mL	18.0943 mL
	10 mM	0.3619 mL	1.8094 mL	3.6189 mL	9.0472 mL
	15 mM	0.2413 mL	1.2063 mL	2.4126 mL	6.0314 mL
	20 mM	0.1809 mL	0.9047 mL	1.8094 mL	4.5236 mL
	25 mM	0.1448 mL	0.7238 mL	1.4475 mL	3.6189 mL
	30 mM	0.1206 mL	0.6031 mL	1.2063 mL	3.0157 mL
	40 mM	0.0905 mL	0.4524 mL	0.9047 mL	2.2618 mL
	50 mM	0.0724 mL	0.3619 mL	0.7238 mL	1.8094 mL
	60 mM	0.0603 mL	0.3016 mL	0.6031 mL	1.5079 mL
	80 mM	0.0452 mL	0.2262 mL	0.4524 mL	1.1309 mL

Keywords

SC66

5 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

SC66

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) SC66

Ver todos los productos específicos de isoformas Akt

Actividad biológica

Chemical Information

Publications (5)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

SC66 Related Classifications

HY-19832 Related Classifications